$Ardelyx(ARDX.US)$ shorts dipping it so they can cover. as long as it stays above 1.45 it will recover to 1.75

$Tesla(TSLA.US)$ the bounce lost its momentum!

$Ardelyx(ARDX.US)$ just one qn. I bought this stock at 1.405 and ever since I left it there but till now it has always been in the range from 1.21-1.24 or sometimes 1.25 and dropped to 1.1+ before so I mean I didn’t spend that much should I hold or just sell.

$Ardelyx(ARDX.US)$ This is a biopharmaceutical company whose products are in the advanced stages of clinical trials. In other words, it's not far from success. Currently, its stock price is at its lowest level in history, and it won't take long for it to rise like a rocket.

$Ardelyx(ARDX.US)$
Citigroup raised the price target on Ardelyx Inc (NASDAQ:ARDX) to $13 from $7, with a Buy rating unchanged.The update follows the Company's plans to launch Ibsrela (tenapanor) for irritable bowel syndrome with constipation (IBS-C) independently in Q2 2022. Analyst Yigal Nochomovitz added IBS-C revenues in the U.S. back to his model and noted that his estimates are in line with management's guidance for $500M at peak, which Nochomovitz sees coming in 2029. He also argues that the Ibsrela launch partially shifts the focus off the formal dispute resolution process with the FDA for hyperphosphatemia and gives Ardelyx another near-term catalyst.Ladenburg upgraded Ardelyx to Buy from Neutral with a $6 price target. Analyst Matthew Kaplan believes the product for IBS-C could generate greater than $400 million in revenues by 2026. Kaplan also notes that Ardelyx announced plans to file a Formal Dispute Resolution Request during Q4 to appeal the CRL for tenapanor for hyperphosphatemia. He looks forward to the filing of the FDRR and more detail on the path forward for this indication.

$Ardelyx(ARDX.US)$ 这只股票已经废了